Titlebook: Adjuvant Chemotherapy of Breast Cancer; Papers Presented at Hans-Jörg Senn Book 1984 Springer-Verlag Berlin Heidelberg 1984 cancer.chemoth

Dri727

Regression and Variable Selection,anges that may further alter the course of breast cancer. The overtone ranges from pessimism to guarded optimism with a general feeling that progress, at least for the time being, has plateaued. Nevertheless, several observations critical to further progress in disease detection and management are b

不发音

,Capture–Recapture Experiments,ve perhaps not been quite as good as many hoped some 5 years ago. In addition, it has become increasingly clear that the side effects of intense chemotherapy may seriously impair the quality of life during the year of administration.

阶层

START

Gianluca Baio,Andrea Berardi,Anna Heathitute. Readers are referred to some of our previous publications [1, 3, 7, 14] for details concerning patient selection, dose schedules, immediate toxic effects, and follow-up studies. For the purpose of this report, suffice it to recall that: (a) the first study (control vs 12 cycles of CMF) was un

set598

占线

,: A User-Friendly Web-App to Use ,,g the past 40–50 years in most countries, increasing numbers of clinical adjuvant studies have emerged during the past decade (reviewed in [3, 16]), prompted particularly by early optimistic reports from the NSABP and Milan groups [1, 5]. Most such investigations included only node-positive (N+) pat

OREX

https://doi.org/10.1007/978-3-319-54274-4 both pre- and postmenopausal patients with operable breast cancer and axillary lymph node involvement. The trial in postmenopausal patients 65 years old or younger (LBCS III), in which the combination of endocrine therapy with multiple cytotoxic chemotherapy was compared with endocrine therapy alon

尊重

让你明白

,The Linear Model: II. The ‘Mixed’ Model, therapy of breast cancer. Over the following 2 years the structure of the Danish Breast Cancer Cooperative Group (DBCG) was organized and in 1977 the first clinical program, DBCG-77, was activated [1, 8]. This paper will briefly review the present status of this program.

GUEER

https://doi.org/10.1007/978-3-319-54274-4and cyclophosphamide (FAC) as adjuvant therapy for stage II and III breast cancer. Earlier results of these studies have been published [1–3]. Here the results of the initial study are presented, with the median follow-up of FAC-treated patients being 85 months. As this is the first adjuvant program